GDC-1261 and INR731 enter phase 1, but how do they act?

The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.

The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.

The FDA apparently deems an uncontrolled study acceptable – five months after saying no.

Could RO7851624, newly into clinical trials, be RG6735?

No sooner does one gammadelta-focused biotech die than another takes its place.